E
eXoZymes Inc.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of eXoZymes Inc.
Revenue$70.1KFY 2023
Operating income−$1.8M
Net profit−$2.0M
Shareholders' equity−$384K
Market cap$37.2MEXOZ · $4.00
Competitors10identified
About eXoZymes Inc.
Sectors
Company details
- Founded
- 2024
- Listed
- Nasdaq: EXOZ (since 2024)
Operational Areas of eXoZymes Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameeXoZymes Inc.
TickerEXOZ
ExchangeNasdaq
CountryUnited States
SEC CIK0002010788
Listed since2024
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
EXOZ · Nasdaq · SEC CIK 0002010788
Last price · 27 Oct 2026
$4.00
+2.56%
Market cap$37.2M
P/E—On FY 2023 diluted EPS
Volume14,308
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 2024
EXOZ share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of eXoZymes Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.